Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Dapagliflozin in Patients with Chronic Kidney Disease Stage 4-5 Under Integrated CKD Care Program: an Investigator-led, Randomized, Open-label, Blinded-endpoint, Multicenter Study

NCT05196347 is registered in ClinicalTrials.gov with Kaohsiung Medical University as lead sponsor.

NCT NCT05196347
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05196347 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Dapagliflozin in Patients with Chronic Kidney Disease Stage 4-5 Under Integrated CKD Care Program: an Investigator-led, Randomized, Open-label, Blinded-endpoint, Multicenter Study
Lead sponsor
Kaohsiung Medical University
Phase
Phase 3
Overall status
Completed
Start date
May 27, 2022
Completion date
August 31, 2024
Enrollment
180 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chronic kidney diseases